Vaxart, Inc. (VXRT)

0.7299 +0.0149 (+2.08%) At close: 04:00PM EST

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 164

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Cezar Andrei Floroiu M.B.A.	CEO, President & Director	674.98k	N/A	1973
Dr. Sean N. Tucker Ph.D.	Senior VP & Chief Scientific Officer	481.52k	N/A	1969
Dr. James F. Cummings M.D.	Chief Medical Officer	526.96k	N/A	1967
Mr. Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1988
Dr. Raymond D. Stapleton Jr., Ph.D.	Chief Technology Officer	N/A	N/A	1971
Mr. Edward B. Berg	Senior VP & General Counsel	N/A	N/A	1965
Ms. Sarah Caravalho Khan	VP & Head of Human Resources	N/A	N/A	N/A
Ms. Shaily Jaini Garg	Senior Vice President of Clinical Development & Project Management	N/A	N/A	N/A
Mr. Brant Biehn	Senior Vice President of Business Operations	N/A	N/A	N/A
Dr. Rajesh Kapoor Ph.D.	Senior Vice President of Quality	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia. The company has license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Corporate governance

Vaxart, Inc.’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.